IGF-DES — Research Overview
Chemical Name: Des(1-3) Insulin-Like Growth Factor-1 Also Known As: IGF-1 DES, IGF-DES, Des(1-3)IGF-I, des-IGF-1, Truncated IGF-1 Structure: 67-amino acid truncated analog of human insulin-like growth factor-1, produced by removal of the first three N-terminal amino acids — the tripeptide Gly-Pro-Glu — from the 70-amino acid native IGF-1 sequence. This creates a truncated form beginning at position 4 (tyrosine) of the native sequence. Natural Origin: Des(1-3)IGF-1 is not purely synthetic — it is a naturally occurring variant of IGF-1. It was first isolated from bovine colostrum and subsequently from human fetal brain tissue. Its existence as an endogenous cleavage product confirms that the body itself produces N-terminally truncated IGF-1 as a physiologically relevant form. Molecular Weight: Approximately 7371 daltons Relationship to Native IGF-1 and IGF-1 LR3: IGF-DES is the shortest of the three principal IGF-1 research variants. Native IGF-1 has 70 amino acids and full IGFBP binding. IGF-DES has 67 amino acids (minus Gly-Pro-Glu), near-eliminated IGFBP binding, approximately 10-fold greater potency than native IGF-1, and an ultra-short half-life of 20 to 30 minutes. IGF-1 LR3 has 83 amino acids (70 native plus a 13-amino acid N-terminal extension and Arg3 substitution), markedly reduced but not eliminated IGFBP binding, approximately 3-fold greater potency than native IGF-1, and a half-life of 20 to 30 hours. The two analogs represent opposite pharmacological design strategies for circumventing IGFBP regulation: LR3 reduces IGFBP binding while extending systemic half-life; DES eliminates IGFBP binding entirely while accepting an ultra-short half-life suited to localized site-specific research applications. Category: Truncated IGF-1 analog / endogenous IGF-1 variant / IGF-1 receptor agonist / localized anabolic and regenerative research peptide
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is IGF-DES?
IGF-DES — formally des(1-3)IGF-1 — is a truncated variant of human insulin-like growth factor-1 produced by removal of the first three N-terminal amino acids (Gly-Pro-Glu) from the native 70-amino acid sequence. Unlike IGF-1 LR3, which is a purely synthetic pharmaceutical design, IGF-DES was first characterized as a naturally occurring variant isolated from bovine colostrum and subsequently from human fetal brain tissue — confirming that N-terminally truncated IGF-1 is not merely a laboratory artifact but an endogenous form of the growth factor with distinct biological properties.
The critical distinction that defines IGF-DES as a research compound is what the removal of those three N-terminal amino acids accomplishes: it eliminates the primary structural determinant responsible for IGF-1’s binding to insulin-like growth factor binding proteins (IGFBPs). Specifically, glutamic acid at position 3 (Glu3) of native IGF-1 has been identified as a key determinant of IGFBP binding affinity. Mutagenesis and structural studies have established that variants like des(1-3)IGF-1 — which lack Glu3 and the flanking Gly1 and Pro2 residues — show dramatically reduced binding to IGFBPs, particularly IGFBP-3 (binding reduced to several times lower affinity) and greatly reduced binding to other IGFBPs.
In circulation, native IGF-1 is almost entirely sequestered by IGFBPs — approximately 98% bound — leaving only a tiny free fraction available for IGF-1 receptor binding. By eliminating IGFBP binding, IGF-DES is essentially 100% bioavailable for IGF-1 receptor interaction at the tissue level. This produces approximately 10-fold greater potency than equivalent molar amounts of native IGF-1 in in vitro and in vivo assays — the most potent enhancement of any characterized IGF-1 variant.
The trade-off is a dramatically shortened half-life of approximately 20 to 30 minutes — far shorter than native IGF-1’s ternary complex half-life of more than 16 hours, and dramatically shorter than IGF-1 LR3’s 20 to 30 hours. This brief duration of action, rather than being purely a limitation, creates a pharmacological profile suited to site-specific localized research: when administered locally to target tissue (typically muscle in research models), IGF-DES produces an intense, transient burst of local IGF-1R activation before being cleared, with minimal systemic exposure and systemic anabolic or hypoglycemic effects.
This localized, high-potency, short-duration profile distinguishes IGF-DES from IGF-1 LR3 and makes them complementary rather than interchangeable research tools: LR3 for sustained systemic IGF-1 axis activation, DES for intense local site-specific receptor stimulation.
Endogenous Origin: Des(1-3)IGF-1 in Colostrum and Fetal Brain
The fact that IGF-DES occurs naturally in bovine colostrum and human fetal brain tissue is scientifically significant. Colostrum — the first milk produced after parturition — is unusually rich in growth factors and contains both intact IGF-1 and des(1-3)IGF-1 as separate molecular species. The presence of the truncated variant in colostrum suggests a physiological role in neonatal tissue growth and intestinal development that is distinct from the role of intact IGF-1 — possibly providing a form of IGF-1 that is not sequestered by neonatal IGFBPs and can directly activate intestinal epithelial and mucosal IGF-1R. Its presence in fetal brain tissue suggests similar physiological relevance in neural development contexts.
This natural occurrence also has structural chemistry significance: the first studies identifying Glu3 as a key IGFBP-binding determinant came specifically from analysis of why des(1-3)IGF-1 binds IGFBPs with greatly reduced affinity compared to native IGF-1. The discovery that removing just three N-terminal residues so dramatically reduces IGFBP affinity while leaving IGF-1R affinity intact provided a foundational insight into the distinct structural requirements for IGFBP versus receptor binding — information that was subsequently used to design other IGFBP-resistant IGF-1 analogs including LR3.
Mechanism of Action
IGF-DES exerts its biological effects as a full agonist of the IGF-1 receptor (IGF-1R), activating the same intracellular signaling cascades as native IGF-1 but with substantially enhanced net potency in the presence of IGFBPs.
IGFBP bypass — enhanced free receptor access: The defining mechanistic feature of IGF-DES is its inability to bind IGFBPs at physiologically relevant concentrations. Whereas native IGF-1 is immediately sequestered upon administration — the large majority binding IGFBP-3 and the acid-labile subunit before it can interact with tissue IGF-1R — essentially all of administered IGF-DES remains in free form available for receptor binding. This accounts for the approximately 10-fold potency advantage over native IGF-1 in tissue assays: it is not that IGF-DES binds the IGF-1R with greater affinity, but that a far greater proportion of each administered dose reaches the receptor.
PI3K/Akt/mTOR pathway: Upon IGF-1R activation, IGF-DES triggers autophosphorylation of the receptor’s tyrosine kinase domains, IRS-1 recruitment and phosphorylation, PI3K activation, Akt phosphorylation, and downstream activation of mTORC1. This cascade drives ribosomal protein translation, protein synthesis initiation, and muscle fiber hypertrophy — the same anabolic signaling pathway activated by native IGF-1 and IGF-1 LR3, but with faster onset kinetics due to immediate receptor access.
FoxO inhibition and anti-atrophy signaling: Akt phosphorylates and inactivates FOXO transcription factors, preventing nuclear translocation and downstream transcription of atrogin-1 (MAFbx) and MuRF1 — the E3 ubiquitin ligases that tag muscle proteins for proteasomal degradation. IGF-DES therefore simultaneously stimulates protein synthesis and suppresses protein degradation within the brief window of its activity.
MAPK/ERK pathway: IGF-1R activation also signals through the MAPK/ERK pathway, driving satellite cell proliferation, myoblast differentiation, and cellular regeneration — effects relevant to IGF-DES’s use in muscle injury and hyperplasia research models.
Hyperplasia versus hypertrophy: A key distinction in IGF-DES research is its proposed capacity to drive both hypertrophy (increased fiber size) and hyperplasia (increased fiber number through satellite cell activation and new myofiber formation) — mechanisms that are studied separately depending on the experimental context, dose, and delivery method. Published research using intraperitoneal injection of des-IGF-1 in mice demonstrated increased phosphorylation of Akt and p70S6K in skeletal muscle, confirming activation of the core hypertrophic signaling cascade in vivo.
Localized site-specific effect: Due to the ultra-short half-life, IGF-DES administered locally to a tissue produces a highly concentrated but temporally brief burst of IGF-1R activation at the site of administration, with rapid clearance limiting systemic exposure. This property is used in research designs that require localized tissue stimulation without the systemic anabolic and hypoglycemic effects that would accompany sustained systemic IGF-1R activation.
Published Research
Study 1 — Endogenous Identification: Des(1-3)IGF-1 in Bovine Colostrum and IGFBP Binding Characterization
Authors: Francis GL, Upton FM, Ballard FJ, McNeil KA, Wallace JC Year: 1988 Journal: Biochemical Journal Referenced via: American Journal of Physiology Endocrinology and Metabolism IGFBP review (full text: https://journals.physiology.org/doi/full/10.1152/ajpendo.2000.278.6.E967)
This was the foundational study identifying des(1-3)IGF-1 as a naturally occurring variant in bovine colostrum, isolated as a distinct molecular species from intact IGF-1. The identification established that N-terminally truncated IGF-1 is not a laboratory artifact but a physiologically produced form of the growth factor with its own distinct binding properties.
Des(1-3)IGF-1 was isolated from bovine colostrum and characterized as having sequences and biological activities that were subsequently compared to native IGF-1, establishing its status as a potent truncated form.
The key binding chemistry finding from early structural studies of des(1-3)IGF-1 — later reviewed in the AJP-Endocrinology IGFBP review — was that this peptide binds to IGFBP-3 with several times lower affinity than natural IGF-1 and shows greatly reduced binding to other IGFBPs, while retaining normal affinity for the IGF-1 receptor.
Glu3 was identified as an important structural determinant of IGFBP binding: variants like des(1-3)IGF-1 — which lack Glu3 — show considerably reduced IGFBP interaction, establishing the molecular basis for the potency enhancement of all N-terminal truncation or Glu3 modification-based IGF-1 analogs.
This study’s identification of des(1-3)IGF-1 as a naturally occurring high-potency IGF-1 variant directly inspired the development of both IGF-DES as a research compound and the conceptual framework for designing IGFBP-resistant IGF-1 analogs.
Study 2 — Des(1-3)IGF-1 Enhances Growth After Gut Resection: Nitrogen Balance and Weight Recovery
Authors: Vanderhoof JA, McCusker RH, Clark R et al. Year: 1992 Journal: American Journal of Physiology — Endocrinology and Metabolism PMID: 1996625 Full text: https://pubmed.ncbi.nlm.nih.gov/1996625/
This in vivo rat study directly compared native IGF-1 at two doses with des(1-3)IGF-1 at an equivalent dose to the lower IGF-1 dose, administered by osmotic infusion pump for 7 days following 80% jejunum-ileum resection in rats — a severe surgical wasting model.
Des(1-3)IGF-1 at 0.96 mg/kg/day produced weight recovery equivalent to native IGF-1 at 2.4 mg/kg/day — demonstrating that the truncated variant achieved equivalent anabolic effect at less than half the administered dose, directly confirming its approximately 2 to 3-fold greater in vivo potency in this model relative to native IGF-1 on a per-weight basis.
Nitrogen balance over the final 3 days of the study was 242 plus or minus 14 mg/day for high-dose IGF-1 and 217 plus or minus 13 mg/day for des(1-3)IGF-1, both significantly more positive than the control group at 153 plus or minus 21 mg/day (P less than 0.05) — establishing that the truncated variant produces real, measurable nitrogen retention consistent with reduced muscle protein breakdown.
The differences in nitrogen retention could at least partially be explained by changes in muscle protein breakdown as assessed by 3-methylhistidine excretion, confirming the anti-catabolic muscle-protective effect of IGF-DES in this surgical wasting context.
Study 3 — Akt and p70S6K Phosphorylation by Des-IGF-1 in Skeletal Muscle In Vivo
Authors: Li et al. (2002, 2003) Referenced via: Journal of Cell Science review (2010) by Shavlakadze et al. Full text: https://journals.biologists.com/jcs/article/123/6/960/31470/
A directly relevant citation from the Journal of Cell Science review of IGF-1 and skeletal muscle hypertrophy documents the specific in vivo signaling effects of des-IGF-1 in skeletal muscle.
Increased phosphorylation of Akt and p70S6K was shown in skeletal muscles following intraperitoneal injection of des-IGF-1 (described as truncated variant of IGF-1 with reduced affinity to IGF-1-binding proteins) into mice, directly establishing that IGF-DES activates the core PI3K/Akt/mTOR hypertrophic signaling cascade in vivo in skeletal muscle tissue.
These findings confirmed that the enhanced in vitro potency of IGF-DES translates to measurable intracellular signaling activation in intact skeletal muscle in living animals, providing mechanistic support for its use in muscle research protocols.
Study 4 — Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy: Comprehensive Mechanistic Framework
Authors: Yoshida T, Delafontaine P Year: 2020 Journal: Cells (MDPI) Full text: https://pmc.ncbi.nlm.nih.gov/articles/PMC7564605/
This comprehensive peer-reviewed review provides the mechanistic framework within which IGF-DES research is conducted, establishing the scientific rationale for the signaling pathways that IGF-DES activates in skeletal muscle.
IGF-1 increases skeletal muscle protein synthesis via PI3K/Akt/mTOR and PI3K/Akt/GSK3-beta pathways — both activated downstream of the IGF-1R that IGF-DES binds as a full agonist.
PI3K/Akt activation inhibits FoxO transcription factors, suppressing E3 ubiquitin ligase-mediated protein degradation — the anti-atrophy arm of IGF-1R signaling that IGF-DES activates during its window of action.
IGF-1 potentiates skeletal muscle regeneration through satellite cell activation — the cellular mechanism by which IGF-DES promotes hyperplasia (new fiber formation) in addition to hypertrophy (increased fiber size) in muscle research models.
The review explicitly references the injection of des-IGF-1 as one of the experimental approaches used to demonstrate Akt and mTOR pathway activation in skeletal muscle in vivo, directly citing the role of this truncated variant in advancing mechanistic understanding of IGF-1 signaling in muscle tissue.
Study 5 — IGFBP Structural Biology and des(1-3)IGF-1 Binding Chemistry: Key Determinants
Authors: Clemmons DR Year: 2001 Journal: American Journal of Physiology — Endocrinology and Metabolism (IGFBP review) Full text: https://journals.physiology.org/doi/full/10.1152/ajpendo.2000.278.6.E967
This authoritative review of IGF-binding protein biology provides the structural chemistry foundation for understanding exactly why des(1-3)IGF-1 has the dramatically reduced IGFBP binding that defines its research properties.
The N-terminally truncated des(1-3)IGF-1 — isolated from bovine colostrum and human fetal brain — binds to IGFBP-3 with several times lower affinity than natural IGF-1 and shows greatly reduced binding to other IGFBPs, while N-terminal truncation variants and point mutations at Glu3 and related positions consistently produce reduced IGFBP interaction.
Whereas IGFBPs consistently have extremely high affinity for native IGF-1, des-IGF-1 and a variety of IGF-1 analogs have markedly reduced affinity for IGFBPs but retain normal affinity for the IGF-1 receptor — directly establishing the mechanistic basis for the 10-fold potency enhancement of IGF-DES over native IGF-1 in the presence of IGFBPs.
The review identifies N-terminal truncated IGF-1 as one of the most valuable reagents in studies of endogenous IGFBP regulatory function, establishing IGF-DES not merely as a muscle research tool but as a foundational probe for understanding the physiology of the entire IGFBP regulatory system.
IGF-DES vs IGF-1 LR3: Two Complementary Research Tools
Researchers choosing between IGF-DES and IGF-1 LR3 are selecting between two fundamentally different pharmacological strategies for circumventing IGFBP regulation. Both compounds are full IGF-1R agonists. Both eliminate most IGFBP binding. But their pharmacokinetic profiles make them suited to different experimental designs.
IGF-1 LR3 reduces IGFBP binding by approximately 70 to 80% while extending half-life to 20 to 30 hours — making it the tool of choice for research requiring sustained, systemic, extended IGF-1 axis activation across cell culture systems, multi-day animal experiments, muscle atrophy reversal studies, and body-composition research.
IGF-DES eliminates IGFBP binding essentially completely while accepting a 20 to 30 minute half-life — making it the tool of choice for research requiring intense, brief, site-specific IGF-1R activation, localized tissue hypertrophy and hyperplasia studies, and experimental designs where minimizing systemic exposure and systemic hypoglycemic risk is a design priority.
Researchers should not use both simultaneously, as they act on the same receptor and produce overlapping effects without additive rationale. The selection between them should be driven by whether the experimental question requires sustained systemic IGF-1 axis engagement (LR3) or localized high-intensity transient receptor activation (DES).
An Important Research Safety Note
IGF-DES shares the same critical safety considerations as all IGF-1 axis research compounds.
Cancer risk: The IGF-1 receptor is overexpressed in many human cancers and IGF-1R signaling drives tumor cell proliferation, survival, and metastasis. Elevated IGF-1 signaling is epidemiologically associated with increased cancer risk. Researchers must consider the oncological implications of IGF-1R agonism in experimental design.
Hypoglycemia risk: Although IGF-DES’s ultra-short half-life limits systemic hypoglycemia risk relative to IGF-1 LR3, cross-reactivity with insulin receptors at elevated concentrations produces insulin-like blood glucose lowering effects. This is relevant even for localized administration at higher concentrations.
WADA classification: IGF-DES is classified as a prohibited substance by WADA under peptide hormones, growth factors, and related substances (S2).
No human clinical trials have been conducted or published using IGF-DES as a standalone compound.
Current Research Status
IGF-DES is not FDA-approved for any indication. It is used as a laboratory research tool in preclinical studies of IGF-1 receptor signaling, skeletal muscle biology, satellite cell activation, localized tissue anabolism, and IGFBP regulatory physiology. No human clinical trials have been conducted.
Reconstitution Note
IGF-DES is a peptide compound. Acetic acid (0.6%) is the recommended primary reconstitution solvent — add acetic acid first, allow the lyophilized powder to dissolve fully, then dilute to working concentration with bacteriostatic water. Always confirm the recommended reconstitution protocol against the specific lot datasheet before use.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light at all stages of storage and handling. Avoid repeated freeze-thaw cycles of reconstituted solutions regardless of the diluent used. Use within the timeframe recommended for the individual compound. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration, or signs of contamination.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard peptide handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the IGF-DES product page: https://roguecompounds.com/product/igf-des/